Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 8:54 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–20 of 20 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Acute Peripheral Arterial Occlusion Clear all
Terminated Phase 3 Interventional

Clopidogrel and the Optimization of Gastrointestinal Events (COGENT-1)

NCT00557921
View directory record Official record
Conditions
Acute Coronary Syndrome, Myocardial Infarction, Coronary Artery Disease, Percutaneous Coronary Intervention
Interventions
CGT-2168 (clopidogrel 75 mg/omeprazole 20 mg) and aspirin, Plavix (clopidogrel 75 mg) and aspirin
Drug
Lead sponsor
Cogentus Pharmaceuticals
Industry
Eligibility
21 Years and older
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
247
States / cities
Alexander City, Alabama • Birmingham, Alabama • Geneva, Alabama + 205 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2009 · Synced Sep 23, 2026, 8:54 PM EDT
Not listed Not applicable Interventional

Effect of Lower Leg Heating and Transcutaneous Electrical Nerve Stimulation on Exercise Capacity in Patients With PAD

NCT03462472
View directory record Official record
Conditions
Peripheral Arterial Disease
Interventions
Lower leg heating, Lower leg transcutaneous electrical nerve stimulation (TENS)
Behavioral
Lead sponsor
Salisbury University
Other
Eligibility
40 Years to 85 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Salisbury, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 11, 2018 · Synced Sep 23, 2026, 8:54 PM EDT
Completed Phase 2 Interventional

Alfimeprase for Thrombolysis in Acute Peripheral Arterial Occlusion

NCT00073554
View directory record Official record
Conditions
Arterial Occlusive Diseases, Peripheral Vascular Diseases, Thrombosis
Interventions
Alfimeprase
Drug
Lead sponsor
ARCA Biopharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 16, 2009 · Synced Sep 23, 2026, 8:54 PM EDT
Enrolling by invitation Early Phase 1 Interventional

Truway Diagnostic Tools in Primary Care

NCT07209527
View directory record Official record
Conditions
Chronic Disease, Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight, Hypertension, Cardiovascular Disease Acute, Hyperlipidemia, Chronic Kidney Disease (CKD), Stages 3-4 Exercise Tolerance / Functional Capacity Vascular Health / Arterial Stiffness Fatigue in CKD, Peripheral Artery Disease, Metabolic Syndrome, Prediabetes
Interventions
Truway Portable Ultrasound Device, Truway Blood Glucose Monitor, Standard Oral Hypoglycemic Agent
Device · Drug
Lead sponsor
Truway Health, Inc.
Industry
Eligibility
Not listed
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 23, 2025 · Synced Sep 23, 2026, 8:54 PM EDT
Completed Phase 3 Interventional Results available

Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome

NCT03473223
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
Apolipoprotein A-I [human] (apoA-I), Placebo
Biological · Other
Lead sponsor
CSL Behring
Industry
Eligibility
18 Years and older
Enrollment
18,226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
202
States / cities
Alexander City, Alabama • Birmingham, Alabama • Huntsville, Alabama + 175 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2025 · Synced Sep 23, 2026, 8:54 PM EDT
Completed Phase 1 Interventional

A Dose Escalation and Safety Study of Plasmin (Human) In Acute Lower Extremity Native Artery or Bypass Graft Occlusion

NCT00418483
View directory record Official record
Conditions
Arterial Occlusive Diseases
Interventions
Plasmin (Human) 25 mg, Plasmin (Human) 50 mg, Plasmin (Human) 75 mg, Plasmin (Human) 100 mg, Plasmin (Human) 125 mg, Plasmin (Human) 150 mg, Plasmin (Human) 175 mg
Biological
Lead sponsor
Grifols Therapeutics LLC
Industry
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Toledo, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 30, 2016 · Synced Sep 23, 2026, 8:54 PM EDT
Completed Phase 2 Interventional Results available

A Study of Intra-thrombus Plasmin (Human) In Acute Peripheral Arterial Occlusion

NCT01222117
View directory record Official record
Conditions
Acute Peripheral Arterial Occlusion
Interventions
Plasmin, Plasminogen Activator, Placebo
Biological · Other
Lead sponsor
Grifols Therapeutics LLC
Industry
Eligibility
18 Years and older
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
2
States / cities
Buffalo, New York • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 15, 2017 · Synced Sep 23, 2026, 8:54 PM EDT
Terminated Phase 3 Interventional

Study of Alfimeprase's Ability to Dissolve Blood Clots in the Leg and Help Prevent the Need for Surgery

NCT00338585
View directory record Official record
Conditions
Arterial Occlusive Diseases
Interventions
alfimeprase
Drug
Lead sponsor
ARCA Biopharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jan 14, 2008 · Synced Sep 23, 2026, 8:54 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities

NCT02504216
View directory record Official record
Conditions
Peripheral Artery Disease
Interventions
Rivaroxaban (Xarelto, BAY59-7939), Rivaroxaban-Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
50 Years and older
Enrollment
6,564 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
105
States / cities
Alexander City, Alabama • Birmingham, Alabama • Fort Payne, Alabama + 91 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2020 · Synced Sep 23, 2026, 8:54 PM EDT
Completed Phase 3 Interventional

Study of Alfimeprase to Rapidly Dissolve Blood Clots in the Leg and Help Prevent the Need for Surgery on Leg Arteries

NCT00115999
View directory record Official record
Conditions
Arterial Occlusive Diseases
Interventions
alfimeprase
Drug
Lead sponsor
ARCA Biopharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 14, 2008 · Synced Sep 23, 2026, 8:54 PM EDT
Terminated Not applicable Interventional Results available

Use of Clearway™ Balloon vs. Mechanical Thrombectomy as Initial Treatment for Acute Limb Ischemia

NCT00869375
View directory record Official record
Conditions
Critical Limb Ischemia
Interventions
Endovascular peripheral intervention
Device
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 85 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jul 20, 2014 · Synced Sep 23, 2026, 8:54 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

The Pharmacokinetics and Pharmacodynamics Study of Evategrel CG-0255 Besylate）and Plavix® in Healthy Participants

NCT07619885
View directory record Official record
Conditions
Acute Coronary Syndromes (ACS), Recent Myocardial Infarction, Recent Stroke, Peripheral Arterial Disease
Interventions
CG-0255 Besylate for Injection, CG-0255 Besylate Capsule, Clopidogrel
Drug
Lead sponsor
Shanghai CureGene Pharmaceutical Co., Ltd.
Industry
Eligibility
18 Years to 55 Years
Enrollment
136 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 28, 2026 · Synced Sep 23, 2026, 8:54 PM EDT
Completed No phase listed Observational Results available

Observational Study to Evaluate PAD Treatment Clinical and Economic Outcomes

NCT01855412
View directory record Official record
Conditions
Peripheral Arterial Occlusive Disease
Interventions
PAD endovascular treatments
Other
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
1,204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
52
States / cities
Gilbert, Arizona • Glendale, Arizona • Phoenix, Arizona + 47 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2023 · Synced Sep 23, 2026, 8:54 PM EDT
Completed Not applicable Interventional

Acute Probiotic Supplementation and Endothelial Function

NCT04364074
View directory record Official record
Conditions
Coronary Artery Disease, Hypertension, Hyperlipidemias, Peripheral Vascular Diseases, Cerebral Arterial Diseases
Interventions
Goodbelly, Placebo
Dietary Supplement
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
21 Years to 89 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Wauwatosa, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 21, 2023 · Synced Sep 23, 2026, 8:54 PM EDT
Recruiting No phase listed Observational

Pounce™ Thrombectomy System Retrospective Registry

NCT05868161
View directory record Official record
Conditions
Peripheral Arterial Disease, Acute Limb Ischemia
Interventions
Pounce Thrombectomy System
Device
Lead sponsor
SurModics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
9
States / cities
Peoria, Illinois • Munster, Indiana • Baton Rouge, Louisiana + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2025 · Synced Sep 23, 2026, 8:54 PM EDT
Recruiting No phase listed Observational

Case-Specific Health Care Professional Clinical Survey of Liberant™ Thrombectomy System

NCT07335341
View directory record Official record
Conditions
Venous Embolism of Lower Extremities (Diagnosis), Arterial Embolism and Thrombosis, Acute DVT of Lower Extremity, Chronic DVT of Lower Extremity, DVT, Deep Vein Thrombosis Leg, Thrombus in the Peripheral Venous Vasculature, Peripheral Arterial Disease, Acute Limb Ischemia, Lower Extremity Acute Limb Ischemia, LE ALI
Interventions
Liberant Thrombectomy System
Device
Lead sponsor
Medtronic Endovascular
Industry
Eligibility
22 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Naples, Florida • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 23, 2026, 8:54 PM EDT
Recruiting Phase 3 Interventional

Low Dose ColchicinE in pAtients With Peripheral Artery DiseasE to Address Residual Vascular Risk

NCT04774159
View directory record Official record
Conditions
Peripheral Arterial Disease, Atherosclerosis of Extremities, Inflammation
Interventions
Colchicine 0.5 MG Oral Tablet, Colchicine-Placebo
Drug
Lead sponsor
Population Health Research Institute
Other
Eligibility
18 Years and older
Enrollment
6,150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
19
States / cities
New Haven, Connecticut • Gainesville, Florida • Tampa, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Sep 23, 2026, 8:54 PM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Multimodal Physiologic State Intelligence Study

NCT07814118
View directory record Official record
Conditions
Heart Failure, Cardiomyopathies, Pulmonary Hypertension, Myocarditis; Acute or Subacute, Myocarditis Due to Drug, Myocarditis Viral, Pericardial Diseases, Valvular Heart Diseases, Hypertension, Sepsis, Acute Kidney Injury, Pulmonary Edema - Acute, Pulmonary Edema With Heart Failure, Pulmonary Edemas, Acute Respiratory Distress Syndrome, Pulmonary Embolism Acute, Pulmonary Embolism (Diagnosis), Pulmonary Embolism Acute Massive, Pulmonary Embolism Subacute Massive, Venous Thrombosis Pulmonary, Venous Thrombosis (Disorder), Venous Thrombosis, Deep, Peripheral Arterial Disease, Peripheral Arterial Disease (PAD), Aortic Diseases, Muskuloskeletal Diseases, Brain Aging, Brain Aneurysm, Brain Aging Related Conditions, Ultrasound, Ultrasound Exams, Ultrasound Guidance
Interventions
OMNIPHYS Multimodal Ultrasound Imaging System
Device
Lead sponsor
Truway Health, Inc.
Industry
Eligibility
18 Years and older
Enrollment
25,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2046
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Sep 23, 2026, 8:54 PM EDT
Completed No phase listed Observational Results available

Post-Market Registry of AURYON Atherectomy Device in Subjects Affected With Infrainguinal Peripheral Artery Disease

NCT04229563
View directory record Official record
Conditions
Infrainguinal Peripheral Artery Disease, Peripheral Arterial Disease, PAD
Interventions
AURYON Atherectomy System
Device
Lead sponsor
Angiodynamics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
10
States / cities
Scottsdale, Arizona • Tucson, Arizona • Davenport, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced Sep 23, 2026, 8:54 PM EDT
Terminated Not applicable Interventional Results available

Effect of Acute Statin Treatment in Patients Undergoing Percutaneous Coronary Intervention

NCT00588471
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Simvastatin, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2011
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 7, 2012 · Synced Sep 23, 2026, 8:54 PM EDT